Select Page

DiaCarta Named to CIO Applications’ “Top 25 Life Sciences Technology Vendors 2018”

by | Jun 4, 2018 | Press Releases

CIO Applications has chosen DiaCarta as one of the Top 25 Life Sciences Technology Vendors 2018. The positioning is based on an evaluation of DiaCarta’s specialty in personalized diagnostics, translational genomics and clinical sample testing services provided in both US and China. The annual list of companies is selected by a panel of experts and members of CIO Applications’ editorial board to recognize and promote technology entrepreneurship.

“We are glad to announce DiaCarta as one among the Top 25 Life Sciences Technology Vendors 2018. We are pleased to recognize DiaCarta for its development, manufacturing and markets cancer research and IVD products for precision molecular diagnostics,” said Joe Phillip, Managing Editor of CIO Applications.

“We are honored to be recognized by CIO Applications,” said Aiguo (Adam) Zhang, CEO and Founder of DiaCarta, “It helps further validate and reaffirm our strategic and technical goals to provide highly sensitive and advanced technologies to redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans.”

About DiaCarta

DiaCarta is a translational genomics and personalized diagnostics company based in Richmond, California with significant business operations in China. DiaCarta provides highly sensitive and advanced XNA technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. With over 20,000 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, DiaCarta is changing the landscape of molecular diagnostics.

About CIO Applications

CIO Applications is a technology magazine, published from Silicon Valley, CA, that is a prime platform for CIOs to discuss and ponder about innovative enterprise solutions. It is a medium that helps upcoming enterprise IT vendors to engage and showcase their solutions for enterprises. CIO Applications helps technology leaders by providing analysis on new technologies and gives a better understanding of the role that enterprise solutions play in achieving business goals.

Lead Source

DiaCarta Expands Board Leadership with Industry Veteran

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Jack Kaye, retired Partner with Deloitte LLP, as an independent board member who will serve as the Chairman of the Company’s Audit Committee.

DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on the evaluation and development of DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology. NCI and DiaCarta will collaborate on the following projects: (1) the investigation of low frequency mutation events in cancers and rare diseases using DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology, and (2) the development of XNA probes for in situ cancer cell detection. The duration of the CRADA will be 2 years from the effective start date.

DiaCarta Receives CE/IVD for its New COVID 19 Test that Identifies Delta Plus and New Variants

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world. This new test screens for the SARS-CoV-2 virus and simultaneously identifies and differentiates all the new mutating COVID 19 variants including the Alpha (UK), Beta (S. Africa), Gamma (Brazil), Delta (India), Delta Plus (India), Epsilon (California) and the Kappa (India) variants.

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X